Literature DB >> 10559000

Characterization of an E-box-dependent cis element in the smooth muscle alpha-actin promoter.

F Jung1, A D Johnson, M S Kumar, B Wei, M Hautmann, G K Owens, C McNamara.   

Abstract

Identification of the regulators of smooth muscle specific gene expression is critical for understanding smooth muscle cell (SMC) differentiation and the alterations in SMC phenotype seen in vascular diseases. Previous studies have identified that a 2-bp mutation in a conserved cis-acting element (TGTTTATC) in the promoter of the chicken smooth muscle (SM) alpha-actin gene abolished nuclear factor binding and decreased transcriptional activity of a 271-bp SM alpha-actin promoter fragment when transfected into rat aortic SMC. However, the promoter region containing this conserved sequence has negative cis regulatory activity when studied in homologous systems. The goal of the present studies was to further characterize the transcriptional activity of the rat SM alpha-actin promoter region between -224 and -236 that is conserved across mammals. DNAse I analysis and electrophoretic mobility shift assays demonstrated that SMC nuclear proteins bound an extended sequence (TGTTTATCCCCATAA). Transient transfection experiments of wild-type and mutant rat SM alpha-actin promoter-luciferase constructs into rat aortic SMC revealed that promoter activity was enhanced by mutations of specific nucleotides in the TGTTTATCCCCA region. Interestingly, the TGTTTATCCCCA element in the rat SM alpha-actin promoter is centered between 2 canonical E-boxes. Mutations of the flanking E-boxes abolished the enhancement in promoter activity seen with mutation of the TGTTTATCCCCA element alone. Thus studies provide evidence for a regulatory cassette in the rat SM alpha-actin promoter that regulates gene expression via combinatorial interactions between 2 E-boxes and a newly described TGTTTATCCCCA element.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10559000     DOI: 10.1161/01.atv.19.11.2591

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  6 in total

Review 1.  Smooth muscle cell phenotypic switching in atherosclerosis.

Authors:  Delphine Gomez; Gary K Owens
Journal:  Cardiovasc Res       Date:  2012-03-08       Impact factor: 10.787

2.  Id3 is a novel atheroprotective factor containing a functionally significant single-nucleotide polymorphism associated with intima-media thickness in humans.

Authors:  Amanda C Doran; Allison B Lehtinen; Nahum Meller; Michael J Lipinski; R Parker Slayton; Stephanie N Oldham; Marcus D Skaflen; Joseph Yeboah; Stephen S Rich; Donald W Bowden; Coleen A McNamara
Journal:  Circ Res       Date:  2010-02-25       Impact factor: 17.367

3.  Global expression profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching.

Authors:  Rachel C Chambers; Patricia Leoni; Naftali Kaminski; Geoffrey J Laurent; Renu A Heller
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

4.  Targeting myofibroblasts in model systems of fibrosis by an artificial alpha-smooth muscle-actin promoter hybrid.

Authors:  Julia Hirschfeld; Julia Maurer; Diana Jung; Monika Kwiecinski; Al Karim Khimji; Hans Peter Dienes; Jochen W U Fries; Margarete Odenthal
Journal:  Mol Biotechnol       Date:  2009-06-24       Impact factor: 2.695

5.  Causal Inference Engine: a platform for directional gene set enrichment analysis and inference of active transcriptional regulators.

Authors:  Saman Farahmand; Corey O'Connor; Jill A Macoska; Kourosh Zarringhalam
Journal:  Nucleic Acids Res       Date:  2019-12-16       Impact factor: 16.971

6.  The transcription factor scleraxis is a critical regulator of cardiac fibroblast phenotype.

Authors:  Rushita A Bagchi; Patricia Roche; Nina Aroutiounova; Leon Espira; Bernard Abrenica; Ronen Schweitzer; Michael P Czubryt
Journal:  BMC Biol       Date:  2016-03-17       Impact factor: 7.431

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.